THOUSAND OAKS, Calif., Oct. 24, 2019 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that effective Dec. 31, 2019, Repatha® (evolocumab), an innovative treatment for patients with high cholesterol ...
Repatha is an effective medication that can lower LDL cholesterol and significantly reduce the risk of heart attacks and strokes. Like most drugs, Repatha can cause side effects. However long-term ...
THOUSAND OAKS, Calif., Aug. 25, 2025 /PRNewswire/ -- Amgen (AMGN) today announced that the U.S. Food and Drug Administration (FDA) has broadened the approved use of Repatha ® (evolocumab) to include ...
PHILADELPHIA—With new competition potentially on its way in the PCSK9 inhibitor class, Amgen's stalwart Repatha is looking for a leg up in treating high-risk heart attack patients. A new analysis ...
The White House’s direct-to-consumer (DTC) platform, TrumpRx, is steadily expanding its catalogue, with products from GSK and Amgen the latest to join the collection of drugs offered through the pr | ...
Previously, Repatha was indicated to reduce the risk of MACE in patients with established cardiovascular disease. The Food and Drug Administration (FDA) has expanded the approval of Repatha ® ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results